CD8+ T cell differentiation and dysfunction in cancer

By M. Philip, A. Schietinger. Nature reviews. Immunology, 2021

857 citations recorded by the source corpus.

CD8+ T cells specific for cancer cells are detected within tumours. However, despite their presence, tumours progress. The clinical success of immune checkpoint blockade and adoptive T cell therapy demonstrates the potential of CD8+ T cells to mediate antitumour responses; however, most patients with cancer fail to achieve long-term responses to immunotherapy. Here we review CD8+ T cell differentiation to dysfunctional states during tumorigenesis. We highlight similarities and differences between T cell dysfunction and other hyporesponsive T cell states and discuss the spatio-temporal factors contributing to T cell state heterogeneity in tumours. An important challenge is predicting which patients will respond to immunotherapeutic interventions and understanding which T cell subsets mediate the clinical response. We explore our current understanding of what determines T cell responsiveness and resistance to immunotherapy and point out the outstanding research questions. CD8+ T cells assume various dysfunctional states during tumorigenesis. Here, the authors describe mechanisms of T cell dysfunction in tumours, and what determines T cell responsiveness and resistance to immunotherapy.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/d95a87c43d5014fd96933d56363344d74343ff49

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies (2024, background): “378 The advent of ICIs, speci ﬁ cally anti-CTLA4 and anti-PD-1/PD-L1 antibodies, have brought about a paradigm shift in cancer therapy and represent a signi ﬁ cant breakthrough in oncology.”